AllSci News
Insightec spinout Lotus Neuro launches brain drug delivery platform
Lotus Neuro, a clinical-stage biotechnology company spun out of focused ultrasound specialist Insightec, launched publicly with a platform designed to...
Disc Medicine’s DISC-3405 reduces phlebotomy needs in Phase II polycythemia vera trial
Massachusetts-based Disc Medicine (Nasdaq: IRON) released Phase II data showing that DISC-3405, an anti-TMPRSS6 monoclonal antibody, sharply reduced...
Insilico’s rentosertib becomes first AI-discovered drug to enter Phase III
Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, the Phase III trial of rentosertib (ISM001-055 / INS018\055) in idiopathic...
Tempus wins USD 9.5m in ARPA-H funding to develop autonomous cardiology AI
Tempus AI (Nasdaq: TEM) secured up to USD 9.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop and clinically validate an...
Roche moves Enspryng toward first approved MOGAD therapy
Roche (SIX: RO; OTCQX: RHHBY) announced a US FDA Priority Review award for a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab),...
Bayer’s Hyrnuo joins Boehringer’s Hernexeos in first-line HER2-mutant NSCLC
The US FDA has granted accelerated approval to Hyrnuo (sevabertinib) for the first-line treatment of adults with locally advanced or metastatic non-squamous...
McGill and Mount Sinai researchers identify PRMT7 as suppressor of CD8+ T cell expansion
A protein arginine methyltransferase acts as a previously unrecognized suppressor of cytotoxic T cell proliferation, offering a potential new target for...
BioNTech ends autogene cevumeran Phase II after OS imbalance favors control
The BNT122-01 Phase II trial of autogene cevumeran in resected colorectal cancer has been terminated after an independent data safety monitoring board...
Lee's Pharm picks up 1cBio's preclinical PARP1 inhibitor for China and SE Asia
Lee's Pharmaceutical Holdings (HKEX: 00950) has licensed exclusive rights to develop, manufacture, and commercialize OC-3, a preclinical selective PARP1...
Independent research teams validate Apeximmune's PLA2G2D target for overcoming anti-PD-1 resistance
A Nature publication has given South San Francisco-based Apeximmune Therapeutics substantial external validation, with two independent research teams...
Stanford spinout TwoStep raises USD 62.5m as lead peptide-drug conjugate clears FDA IND
San Carlos, California-based TwoStep Therapeutics has raised USD 62.5 million in an oversubscribed Series A financing round, coinciding with US FDA...
Alebund gains FDA IND clearance for IgA-cleaving AP308 in IgA nephropathy
Alebund Pharmaceuticals (HKEX: 09637) received US FDA clearance of its investigational new drug (IND) application for AP308, an engineered recombinant IgA...
IDEAYA, Servier expand darovasertib into Phase III adjuvant uveal melanoma
San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and France-based Servier announced that the first patient has been dosed in OptimUM-11, a global Phase...
InnoCare gains China IND clearance for PSMA/STEAP1 bispecific ADC ICP-B381
China's drug regulator has cleared InnoCare Pharma (HKSE: 9969) to begin clinical testing of ICP-B381, a bispecific antibody-drug conjugate (ADC) designed...
Kura launches Caspian with USD 50m to advance menin inhibition in diabetes
A USD 50 million financing round has backed the launch of Caspian Therapeutics, a newly formed company spun out of San Diego-based Kura Oncology (Nasdaq:...
The AllSci Brief
Free, systematic R&D and deal news. Daily.